Cited 0 times in
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients : a single cancer center experience in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 홍민희 | - |
dc.date.accessioned | 2017-07-07T16:10:38Z | - |
dc.date.available | 2017-07-07T16:10:38Z | - |
dc.date.issued | 2015 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/148790 | - |
dc.description | 의과대학/석사 | - |
dc.description.abstract | Purpose : The retrospective study was performed to assess the efficacy and toxicity profiles of sunitinib in Korean patients with metastatic renal cell carcinoma (RCC). Materials and Methods : Between January 2005 and December 2008, 76 Korean patients with recurrent/metastatic RCC who received sunitinib were retrospectively reviewed. The primary end point was progression-free survival and the secondary end points were overall survival and response rate. We also assessed the toxicities associated with sunitinib treatment. Results : Of the 76 patients, 68 patients (89.5%) were diagnosed with clear cell RCC. The median progression-free survival and overall survival were 7.2 and 22.8 months, respectively in overall patients. Sixty-two patients (81.6%) received 50mg 4 week and 2 week off schedule, and 14 patients (18.4%) received 37.5mg daily on a daily continuous schedule. The objective response rate and disease control rate were 27.6% and 84.2%, respectively. A dose interruption or reduction in dose due to adverse events occurred in 76% of the patients, whereas 12% of these patients had discontinued treatment. Other common laboratory abnormalities were increased serum creatinine (75.6%), elevated alanine aminotransferase (71.0%), neutropenia (61.8%), anemia (69.7%), and increased aspartate aminotransferase (53.3%). Grade 3/4 toxicities occurred as follows: thrombocytopenia (38.2%), fatigue (10.5%), stomatitis (10.5%), and hand-foot syndrome (9.2%). Conclusion : Our results indicate that sunitinib treatment is effective and tolerable for recurrent/metastatic RCC patients in Korea. Further studies with prognostic or biochemical factors are needed to clarify the different toxicity profiles of this study. | - |
dc.description.statementOfResponsibility | open | - |
dc.publisher | Graduate School, Yonsei University | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients : a single cancer center experience in Korea | - |
dc.type | Thesis | - |
dc.contributor.alternativeName | Hong, Min Hee | - |
dc.type.local | Thesis | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.